LONDON, Dec 16 (Reuters) – The U.S. Food and Drug Administration has approved GSK’s add-on drug to treat asthma and a chronic inflammatory sinus condition, the drugmaker said on Tuesday, paving the way for a less frequently dosed treatment option for patients to enter the market.
(Reporting by Bhanvi Satija in London, Sahil Pandey and Sneha S K in Bengaluru; Editing by Tasim Zahid and Shailesh Kuber)
